Avenzo Therapeutics Closes Merger With Rallybio, Alongside $215 Million Placement
Avenzo Therapeutics announced the closing of its merger with Rallybio Corporation and referenced a previously announced $215 million concurrent private placement.
Story updates
09:30:10 PM UTC
SquawkNews
Merger creates Nasdaq-listed, clinical-stage oncology company; shares expected to begin trading as “